Foods like sauerkraut, kimchi, kefir, and tempeh offer an easy way to support that balance
Instead, it may work best when integrated into a comprehensive care plan
Individual responses to GLP-1 therapy are influenced by baseline health status, concurrent medications, dietary habits, and lifestyle factors
Sepsis emerged as the most common cause of AKI in this study, accounting for 55.2% of cases, followed by cardiorenal syndrome at 34.2% (Table S1 )
Medications we offer Weight Loss In Stock Compounded Tirzepatide (GLP-1/GIP) $359/mo for month-to-month plan) Weight Loss In Stock Compounded Semaglutide (GLP-1) $249/mo for month-to-month plan) Weight Loss In Stock Ozempic (Active Ingredient: Semaglutide) Weight Loss In Stock Zepbound (Active Ingredient: Tirzepatide) (*) Compounded medications have not been evaluated or approved by the FDA for safety, efficacy, or quality